Comorbidities and Risk-Benefit Discussions in the Adjuvant Setting

The faculty examine how comorbidities factor into the adjuvant treatment decision for the 68-year-old patient, who carries a cardiac history and diabetes. Dr Whitman frames adjuvant therapy as an inherently probabilistic risk-benefit conversation, since no measurable disease remains and the benefit is a reduction in future recurrence risk rather than an observable response. Dr In describes how he counsels patients on immune-related adverse events in this setting, including the specific concern of immune-related myocarditis in a patient with preexisting cardiac disease. The faculty discuss the role of a baseline echocardiogram, the value of confirming that the patient is well managed by cardiology and primary care before initiating therapy, and how coordinated comorbidity management supports safe treatment. Dr In concludes that adjuvant checkpoint inhibitor therapy remains very reasonable for a patient like this whose other medical issues are stable and well controlled.